TME Pharma

Dr. Maurizio PetitBon (chair)

Co-founder, Kreos Capital

more

Dr. PetitBon is general partner and co-founder of Kreos Capital where he focuses on healthcare investments. Prior to co-founding Kreos, Maurizio was managing partner of PMA Europe, London, a consulting partnership focused on assisting private equity firms and corporate clients in evaluating investment opportunities in technology companies. Prior to that, he was principal consultant at SRI International, in Menlo Park, California and London where he advised a number of U.S., European and Japanese technology companies on business development and M&A strategies. He also held a number of managerial positions at Emerson Electric, Digital Equipment and Xerox. Dr. PetitBon holds a doctor’s degree in mechanical engineering from the University of Rome and an MBA from INSEAD in Fontainebleau, France.

Dr. Martine J. van Vugt (deputy chair)

Senior Vice President Corporate Strategy and Planning, Genmab

more

Dr. Martine J. van Vugt is a senior biopharma executive with 20 years of successful biotechnology industry experience. She is an inventor of Tepezza® (FDA approval in Jan 2020) and the blockbuster product Darzalex® (human CD38 antibody for treatment of Multiple Myeloma). She is an expert in corporate transactional and licensing operations, such as strategic partnering, in- and out-licensing, as well as asset divestment and purchases and led negotiations of over 20 partnering deals, including partnerships with Janssen, Novartis, BioNTech, Immatics and CureVac.
Martine started her professional career at Genmab in 2001, where she currently holds the position of Senior Vice President Corporate Strategy and Planning. Martine also holds board positions at Holland Bio, a non-profit organization representing the biotech industry in the Netherlands, and at Immagene B.V., a startup biotech company active in the field of small molecule development for immuno-oncology targets. Martine holds an M.Sc. in biology from the University of Wageningen and a Ph.D. in immunology from Utrecht University.

Susan Coles

General Counsel and Head of Finance, Vivet Therapeutics 

more

Susan Coles is a specialist in corporate law with over 25 years of experience in international collaborations and corporate/commercial activities, including more than 15 years in the life sciences sector. Susan is General Counsel and Head of Finance at Vivet Therapeutics, a private gene therapy biotech company with a strong investor base, including Roche Venture Fund, Novartis Venture Funds, HealthCap, Columbus Venture Partners, Kurma Partners, Ysios Capital, Idinvest Partners and Pfizer Inc.
Prior to joining Vivet Therapeutics, Susan was General Counsel for 3 years at Stallergenes, a global leader in allergy immunotherapy, and has also acted as General Counsel for 4 years at Inventiva, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq.
Between 2002-2012, Susan was a Senior Counsel in charge of Licensing and Acquisitions at Laboratoires Fournier and subsequently at Solvay Pharmaceuticals, after its acquisition of Laboratoires Fournier.
Prior to these experiences, Susan worked for 7 years in the field of international partnerships and mergers and acquisitions. Susan has a strong track record in advising senior management on strategic and operational matters as well as broad experience in business negotiation and strategic transactions. She holds a B.A. in Psychology from the University of British Columbia, and an LLB from the University of Toronto. Susan is an attorney of the Bar of Ontario and the New York Bar.

Dr. C. A. (Oscar) Izeboud

CEO, Scenic Biotech 

more

Dr. C. A. (Oscar) Izeboud is CEO of Scenic Biotech, a drug discovery and development company focused on genetic modifiers, based in the Netherlands. Before joining Scenic Biotech, Dr. Izeboud was Managing Director at NIBC Bank N.V. in Amsterdam, where he headed a life sciences and healthcare team and led corporate finance and capital markets activities with a focus on innovative companies. Prior to that, as Managing Director at Kempen & Co., a Dutch investment bank, he built the Life Sciences and Healthcare franchise and played a pivotal role in numerous international transactions in biotech, medtech, and the healthcare industry. Before his transition to the banking sector, Dr. Izeboud’s initial interest was in the biotech industry where he spent a number of years working for Crucell NV, Specs BV, and TNO Pharma.
Dr. Izeboud has been a nonexecutive member of the board of directors of Luciole Medical AG since 2019. He holds a Ph.D. in immunopharmacology from the University of Utrecht in the Netherlands.

 

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.